For instance, hydroxychloroquine and methotrexate have both been found to reduce CVD risk in rheumatoid arthritis.[59, 60] Sarilumab and ziltivekimab, monoclonal antibodies targeting the IL‐6 receptor and IL‐6, are being evaluated for their effects on cardiovascular risk in patients with rheumatoid arthritis (NCT04350216) and chronic kidney disease (NCT05021835) with high CRP levels, respectively. This evidence concerns the gene CRP and chronic kidney disease.